2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index; 152 of the 254 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care chapter provides updated recommendations for diagnosing and classifying diabetes, prediabetes, and related forms, including diagnostic thresholds, screening intervals, and classification categories. It emphasizes confirmatory testing, A1C limitations, risk-based screening, and special populations such as type 1 diabetes, gestational diabetes mellitus (GDM), cystic fibrosis–related diabetes (CFRD), posttransplantation diabetes mellitus (PTDM), pancreatic diabetes, and monogenic diabetes.
Key findings
- Diabetes diagnostic criteria: A1C ≥6.5% (≥48 mmol/mol), FPG ≥126 mg/dL (≥7.0 mmol/L), 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during 75-g OGTT, or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemic symptoms/crisis; absent unequivocal hyperglycemia, diagnosis requires two abnormal results. Prediabetes is defined by A1C 5.7–6.4% (39–47 mmol/mol), FPG 100–125 mg/dL (5.6–6.9 mmol/L; IFG), or 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L; IGT).
- Classification includes type 1 diabetes (5–10% of diabetes), type 2 diabetes (90–95%), specific types due to other causes, and GDM. Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes; type 1 diabetes staging shows ~44% 5-year risk of symptomatic disease at stage 1 and ~60% risk by 2 years and ~75% within 5 years at stage 2.
- Screening: begin at age 35 years for all adults; consider earlier in adults with overweight/obesity plus one or more risk factors; repeat at minimum 3-year intervals if normal. In children/adolescents, consider risk-based screening after puberty or age 10 years, whichever is earlier, with overweight/obesity plus risk factors.
- Special populations: GDM screening at 24–28 weeks; one-step IADPSG criteria increase GDM diagnosis (e.g., 11.5% vs 4.9% in a 2021 USPSTF review) without demonstrated improved health outcomes. CFRD occurs in about 20% of adolescents and 40–50% of adults with cystic fibrosis; annual OGTT screening begins by age 10, and A1C is not recommended for screening due to low sensitivity. PTDM diagnosis is best made once stable on immunosuppression, usually at least 45 days after transplantation, with OGTT preferred. Monogenic diabetes accounts for <5% of diabetes; 80–85% of neonatal diabetes cases have a monogenic cause, and 30–50% of KATP-related neonatal diabetes improves with high-dose oral sulfonylureas.
Methods
- Design: ADA Standards of Care clinical practice guideline/consensus recommendations, updated annually by the ADA Professional Practice Committee, an interprofessional expert committee.
- Data/sample: No primary study sample; the chapter synthesizes published evidence and expert consensus. It references an ADA evidence-grading system (A/B/C/E) detailed in the Introduction and Methodology.
- Main analysis: Narrative synthesis of diagnostic, classification, and screening evidence with graded recommendations; no meta-analysis or primary data collection is reported in this chapter.
Limitations
- Stated evidence gaps include insufficient evidence for continuous glucose monitoring (CGM) for screening/diagnosis of prediabetes or diabetes; unknown optimal screening interval; uncertain benefit of treating early abnormal glucose metabolism; lack of randomized controlled trials for treating versus not treating GDM diagnosed by IADPSG but not Carpenter-Coustan criteria; and limited data on how treating maternal hyperglycemia affects offspring metabolic outcomes.
- Stated classification/diagnostic limitations include common misdiagnosis (e.g., ~40% of adults with new type 1 diabetes), poorly understood type 2 diabetes genetics, inadequate genetic data in diverse populations, and A1C unreliability in conditions such as hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss/transfusion, or erythropoietin therapy.
- Evident from the text: this is a consensus guideline rather than a primary systematic review or meta-analysis; recommendations are graded A/B/C/E, with some based on expert consensus (E), and many cited studies are observational/cohort rather than randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2.1 Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. 1 No single clinical feature con fi rms type 1 diabetes in isolation. 2 Glutamic acid decarboxylase (GAD) should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) where these tests are available. In individuals who have not been treated with insulin, antibodies against insulin may also be useful. In those diagnosed at < 35 years of age who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes, since 5 -10% of people with type 1 diabetes do not have antibodies. 3 Monogenic diabetes is suggested by the presence of one or more of the following features: A1C < 58 mmol/mol ( < 7.5%) at diagnosis, one parent with diabetes, features of a speci fi c monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, and severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model probability > 5% (diabetesgenes.org/exeter-diabetes-app/ModyCalculator). 4 A C-peptide test is only indicated in people receiving insulin treatment. A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptide stimulation test in the context of classi fi cation. If the result is $ 600 pmol/L ( $ 1.8 ng/mL), the circumstances of testing do not matter. If the result is < 600 pmol/L ( < 1.8 ng/mL) and the concurrent glucose is < 4 mmol/L ( < 70 mg/dL) or the person may have been fasting, consider repeating the test. Results showing very low levels (e.g., < 80 pmol/L [ < 0.24 ng/mL]) do not need to be repeated. Where a person is insulin treated, C-peptide must be measured prior to insulin discontinuation to exclude severe insulin de fi ciency. Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 5 Features of type 2 diabetes include increased BMI ( $ 25 kg/m 2 ), absence of weight loss, absence of ketoacidosis, and less marked hyperglycemia. Less discriminatory features include non-White ethnicity, family history, longer duration and milder severity of symptoms prior to presentation, features of the metabolic syndrome, and absence of a family history of autoimmunity. 6 If genetic testing does not con fi rm monogenic diabetes, the classi fi cation is unclear and a clinical decision should be made about treatment. 7 Type 2 diabetes should be strongly considered in older individuals. In some cases, investigation for pancreatic or other types of diabetes may be appropriate. 8 A person with possible type 1 diabetes who is not treated with insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. 9 C-peptide values 200 -600 pmol/L (0.6 -1.8 ng/mL) are usually consistent with type 1 diabetes or maturity-onset diabetes of the young but may occur in insulin-treated type 2 diabetes, particularly in people with normal or low BMI or after long duration. Reprinted and adapted from Holt et al. (36).](https://figures.cochat.ai/paper-figures/7be96ed282694b1c85997763e16ae474/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes2024-i-figure-1.png)

Verification
Claims the paper makes
99 Valid · 9 Not valid · 35 Not checked · 32 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However , in 2003 the ADA adopted the new range of 100 -125 mg/dL (5.6 -6.9 mmol/L) to better de fi ne IFG so that the population risk of developing diabetes with IFG would be similar to that with IGT (11).”
What the sources say
- Disputedcites [11] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care sourceExperimental — accuracy not yet measured
In “The new criteria” (p. 8), the committee defines IFG as fasting plasma glucose of 110 to <126 mg/dL, not 100–125 mg/dL. The paper describes both IFG and IGT as risk factors for future diabetes, but it does not say the lower IFG threshold was adopted to make their population risks similar. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In most cases, such stressor steroidinduced hyperglycemia resolves by the time of discharge (142,143).”
What the sources say
- Partly supportedcites [142] Thomas, 2000, Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes, BMC Nephrol sourceExperimental — accuracy not yet measured
The Results (Hyperglycaemia; page unavailable) show that mean glucose fell from immediately after surgery to the morning of day 2. The Discussion (page unavailable) describes steroid exposure and postoperative hyperglycaemia, but the paper does not report whether most patients’ hyperglycaemia resolved by discharge. (LLM, conf=0.82)
- Disputedcites [143] Chakkera, 2009, Hyperglycemia during the immediate period after kidney transplantation, Clin J Am Soc Nephrol sourceExperimental — accuracy not yet measured
The Abstract (Results) says hyperglycemia was sustained throughout hospitalization and that 66% of patients without pretransplantation diabetes required insulin at discharge. The Discussion says the authors did not know what proportion would ultimately recover, rather than finding that most cases resolved by discharge. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Because periodontal disease is associated with diabetes, the utility of screening in a dental setting and referral to primary care as a means to improve the diagnosis of prediabetes and diabetes has been explored (108 -110)”
What the sources say
- Not checked — no full text of the sourcecites [108] Lalla, 2013, Dental findings and identification of undiagnosed hyperglycemia, J Dent Res source
- Not checked — no full text of the sourcecites [109] Lalla, 2011, Identification of unrecognized diabetes and pre-diabetes in a dental setting, J Dent Res source
- Supportedcites [110] Herman, 2015, Screening for prediabetes and type 2 diabetes in dental offices, J Public Health Dent source
The Discussion (page unavailable) describes periodontal disease and its sequelae as risk factors for dysglycemia, supporting the general association claimed. The paper’s own Results (page unavailable) found no association between clinical evidence of periodontitis and dysglycemia in its study sample, so it should not be cited as demonstrating that association in this cohort. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”
What the sources say
- Partly supportedcites [82] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The epidemiologic studies that formed the basis for recommending A1C to diagnose diabetes included only adult populations (112).”
What the sources say
- Could not verifycites [112] Cowie, 2010, Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006, Diabetes Care sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) says an international expert committee recommended A1C for diagnosis, but does not give the ages of participants in the epidemiologic studies behind that recommendation. The Research Design and Methods section (page unavailable) includes participants aged 12 and older in this paper’s own analysis; that does not establish the ages in the studies the committee relied on. Searches for adult-only evidence and pediatric populations did not resolve the claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 46 with their cited sources checked
Create a free account to see all 175 claims and to verify the 3 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbA1c can be affected by some non-glycaemic factors, including anaemia due to iron deficiency or malaria, specific haemoglobin variants (eg, HbS and HbF), other haemoglobinopathies, polycythaemia due to living in high altitude, liver and kidney diseases, HIV, and specific drugs such as antiretroviral therapy for HIV.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinical guidelines recommend using a second confirmatory test for diabetes diagnosis and initiating treatment,6,21–23 although there is variation in this guidance.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Research works printed but not linked: 1
- International Diabetes Federation . IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021. Accessed 26 September 2023. Available from https://www.diabetesatlas.org/atlas/tenth-edition/
Cited by
Items 501–600 of 2,029
Research Progress in the Relationship between Intestinal Flora and Diabetes Mellitus
Lai, Y., Huang, X., Sun, H., Hui, Q., & Hu, S. (2024) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303308965240624054156 · Cited by 4
Trandafir, A.-I., Ghemigian, A. M., Ciobica, M.-L., Nistor, C., Gurzun, M., Nistor, T. V. I., Petrova, E. N., & Carşote, M. (2024) · Biomedicines · doi:10.3390/biomedicines12071606 · Cited by 6
“Of note, all these mentioned studies used the American Diabetes Association (ADA) criteria for the diagnosis of diabetes (across different years) [46–51].”
ResultGenetic Drivers of Cardiovascular Risk among South Asian Adults
Gami, A., Bhattacharya, R., Natarajan, P., & Patel, J. (2024) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-024-00741-w · Cited by 7
“Accordingly, American Diabetes Association guidelines recommend screening for T2D with BMI ≥ 23 kg/m 2 for Asian Americans, compared to the traditional threshold of ≥ 25 kg/m 2 [30].”
Sultana, S., Nomura, S., Ng, C. F. S., & Hashizume, M. (2024) · AJPM Focus · doi:10.1016/j.focus.2024.100273 · Cited by 4
Kelly, C. S., Wolf, W. A., CORNELIUS, E. M., Peter, M. E., CHAPMAN, K. S. M., & Dunne, J. L. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01637-z · Cited by 7
“Current clinical guidance suggests measuring autoantibodies in symptomatic individuals when a T1D diagnosis is suspected or when a type 2 diabetes mellitus progression occurs faster than expected [6–8].”
BackgroundTakahashi, F., Okada, H., Hashimoto, Y., Kurogi, K., Murata, H., Ito, M., & Fukui, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-71383-6 · Cited by 10
Economic analysis of diabetes type 1 screening in children in the Russian Federation
Nedogoda, S. V., Galstyan, G. R., Лаптев, Д. Н., Salasyuk, A. S., Barykina, I. N., Lutova, V. O., & Popova, E. A. (2024) · Medical Technologies Assessment and Choice · doi:10.17116/medtech202446031104 · Cited by 4
Common mistakes concerning diabetes management in daily clinical practice
Makrilakis, K., & Papachristoforou, E. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.09.004 · Cited by 6
Low hemoglobin, even within the normal range, is associated with diabetic kidney disease
Wang, W., Wang, Y., Tang, F., Liu, H., Lee, Y., Andrikopoulos, S., & Lou, Q. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101580 · Cited by 8
Krysiak, R. G., Kowalcze, K. E., & Okopień, B. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6144 · Cited by 4
Popa, M. M., Sîrbu, A. M., Malinici, E. A., Copăescu, C., & Fica, S. V. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1440250 · Cited by 9
KOJIMA, K., Nakamura, N., Hayashi, A., Kondo, S., Miyabe, M., Kikuchi, T., Sawada, N., Saiki, T., Minato, T., Ozaki, R., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010979 · Cited by 6
“The glucose level criteria for diagnosis of diabetes are fasting plasma glucose level ≥ 126 mg/dL, 2 h plasma glucose level ≥ 200 mg/dL on oral glucose tolerance test, or plasma glucose level ≥ 200 mg/dL at any time [5].”
BackgroundFarhat, C., Xega, V., & Liu, J. (2024) · Medical Review · doi:10.1515/mr-2024-0039 · Cited by 4
Al-Lahham, Y., Volanski, W., Signorini, L., do Prado, A. L., Valdameri, G., Moure, V. R., Welter, M., Alves, A. C., Sari, M. H. M., Rego, F. G. D. M., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12122651 · Cited by 6
“Moreover, the GDM group met the expected diagnosis criteria after excluding pregnant women with pre-gestational diabetes and diabetes during pregnancy, as per official guidelines [39].”
InfluentialLopes, G. W., Canhada, S., dos Reis, R. C. P., Diniz, M. D. F. H. S., Goulart, A. C., Faria, L. C., Griep, R. H., Perazzo, H., Duncan, B. B., & Schmidt, M. I. (2024) · Cadernos de Saúde Pública · doi:10.1590/0102-311xen009924 · Cited by 5
Evaluating the Overall Safety of Glucokinase Activators in Patients with Type 2 Diabetes Mellitus
Liang, T., Cao, M.-J., Wang, Q., Zou, J.-S., Yang, X., Gu, L., & Shi, F. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s474280 · Cited by 4
The impact of metabolic health on fibromyalgia: insights from insulin resistance and related indexes
Karaman, S. T., Hüner, B., & Basat, O. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2439244 · Cited by 6
“[15].”
Kosho, M. X. F., Verhelst, A. R. E., Teeuw, W. J., van Bruchem, S., Nazmi, K., Gerdes, V. E. A., & Loos, B. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247512 · Cited by 5
“A HbA1c measurement of ≥ 5.7% (39 mmol/mol) was used as the cut-off point for a hyperglycemic state, as is recommended by the American Diabetes Association (ADA) [40].”
InfluentialLe, Q. A., Kiener, T., Johnson, H. A., Li, K. H., Limburg, P. J., Fendrick, A. M., Kisiel, J. B., & Ebner, D. W. (2024) · Preventive Medicine · doi:10.1016/j.ypmed.2024.108213 · Cited by 5
IFN-α Neutralizing Antibodies Distinguish LADA From Early-onset Type 1 Diabetes
Amendolara, R., D’Onofrio, L., Sessa, R. L., Giulio, S. D., Mignogna, C., Coraggio, L., Schirano, R., Zampetti, S., Malandrucco, I., Pozzilli, P., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf001 · Cited by 3
Armijo-Borjon, G., Miranda-Aguirre, A. I., Garza‐Silva, A., Fernández‐Chau, I. F., Sanz‐Sánchez, M. Á., González‐Cantú, A., & Romero-Ibarguengoitia, M. E. (2025) · Archives of Dermatological Research · doi:10.1007/s00403-024-03688-5 · Cited by 4
“The diagnosis of psoriatic arthritis, T2DM based on ADA [15 ] criteria, obesity based on the BMI [16], systemic arterial hypertension based on AHA guidelines [ 17], inflammatory bowel disease meeting diag - nostic criteria for Crohn’s disease or ulcerative colitis, his - tory of ischemic heart…”
Efficacy of myo‐inositol and zinc on insulin resistance in a paediatric population with obesity
Antoniotti, V., Partenope, C., Solito, A., Mancioppi, V., Baima, J., Medina, F., Dimarakis, S., Agostini, A., Sista, M. T., Monzani, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16185 · Cited by 4
Kang, S. H., Pack, K. M., Kim, J. H., & Jang, A. Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-87868-x · Cited by 5
“Individuals with DM were defined as those who met at least one of the following criteria: use of DM medications, or fasting blood glucose levels of 126 mg/dL or higher 40–42 .”
Bombonato, M., Beccuti, G., Benso, A. S., Giannone, B., Bertaina, S., Broglio, F., & Bioletto, F. (2025) · HORMONES · doi:10.1007/s42000-025-00632-8 · Cited by 7
“When he first came to the attention of the authors, prandial insulin therapy was stopped, and dapagliflozin 10 mg/day was added to therapy.”
Al-Gadi, I., AlRuthia, Y. S., Mujammami, M. H., Aburisheh, K. H., Alotaibi, M. S., Issa, S. A., Alsaif, A., Seftel, D., Tsai, C., & Khalifah, R. A. A. (2025) · JMIR Research Protocols · doi:10.2196/70575 · Cited by 8
“The diagnosis of T1D in index cases is based on the American Diabetes Association criteria [22], and T1D classification is determined by a clinical diagnosis from a specialized endocrinologist, with or without confirmatory islet autoantibodies testing.”
Taormina, V. M., Eisenhardt, S., Gilbert, M. P., Poynter, M. E., Kien, C. L., & Kraft, J. (2025) · Nutrition Research · doi:10.1016/j.nutres.2025.02.005 · Cited by 5
Abernethy, D., Bennie, J. A., & Pavey, T. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/7466757 · Cited by 5
“This association is deeply intertwined with Type 2 diabetes (T2D) mellitus (T2DM), a chronic health condition typi fi ed by insulin resistance, beta-cell dysfunction, and elevated blood glucose that causes gradual harm to the cardiovascular, kidney, nervous, and ocular systems [2, 3].”
Mesa, A., Puig-Jové, C., Pané, A., Vinagre, I., López‐Quesada, E., Meler, E., Alonso-Carril, N., Quirós, C., Amor, A. J., & Perea, V. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02719-3 · Cited by 4
“Diagnoses of T1D and pre-eclampsia were made according to internationally recommended criteria [20, 21].”
Sun, F., Yu, X.-J., Huang, X., Jin, L., Zhang, J., Xu, Y., Yang, W., & Wang, X. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02566-x · Cited by 4
“Diabetes was defined as self-reported diagnosis, or employing diabetes medication, or fasting glucose levels (detected by hexokinase method) ≥ 7 mmol/L, or GH (HbA1c) levels ≥ 6.5% [20].”
InfluentialElhady, F., Ali, A. A., Elkholy, N. S., et al. (2025) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-025-03415-9 · Cited by 4
Wang, Z., Shi, F., Wang, L., & Fang, C. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01754-0 · Cited by 5
Trejo-González, N. L., Palomar-Morales, M., Baiza-Gutman, L. A., Díaz-Rosas, G., Ortega‐Camarillo, C., & Contreras‐Ramos, A. (2025) · Metabolites · doi:10.3390/metabo15060367 · Cited by 6
“Diagnostic thresholds are a fasting glucose concentration greater than 92 mg/dL, 180 mg/dL at 1 h, or 153 mg/dL at 2 h after a glucose challenge [2].”
Steatotic liver disease as a risk enhancer in the presence of metabolic syndrome
Zeng, G., Wang, P., Xu, W., Li, Q., Li, T., Tian, Y., Huang, B., Grobbee, D. E., Cabezas, M. C., & Yuan, J. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf330 · Cited by 5
Association Between Diabetes Mellitus and Left Atrial Strain in Individuals With Hypertension
Guida, C. M., Souza, J. B., Cesena, F. Y., Laurinavicius, A. G., de Sousa, M. G., Vilela, A. D. A., Consolim‐Colombo, F. M., & Assef, J. E. (2025) · Echocardiography · doi:10.1111/echo.70226 · Cited by 5
“Diabetes mellitus was defined according to the diagnostic criteria established by the American Diabetes Association [16].”
Thomsen, H. B., Li, L. Y., Isaksen, A. A., Lebiecka-Johansen, B., Bour, C., Fagherazzi, G., van Doorn, W. P. T. M., Varga, T. V., & Hulmán, Á. (2025) · PLOS Digital Health · doi:10.1371/journal.pdig.0000918 · Cited by 4
Deethai, P., Siriwathanakul, C., Pitchakarn, P., Imsumran, A., Wongnoppavich, A., Dissook, S., & Chewonarin, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178176 · Cited by 6
“Diabetes is a common metabolic disorder characterized by chronic hyperglycemia resulting from defects in insulin production or action [1].”
Liu, X., Xu, Q., Zhang, L., & Liu, H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308343 · Cited by 5
Luo, B., Xu, W., Ye, D., et al. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s469368 · Cited by 4
Yang, C., Ji, L., & Han, X. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae602 · Cited by 4
Carbohydrate Counting: A Bibliometric Analysis with a Focus on Research
Kavcar, S. Y., Köse, G., KARACA, K. E., Çelik, A., & Baş, M. (2024) · Nutrients · doi:10.3390/nu16193249 · Cited by 4
Okawa, Y., Mitsuhashi, T., & Suzuki, E. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02601-8 · Cited by 3
“HbA1c ≥ 6.5% was defined as prevalent diabetes [22].”
InfluentialKidney Transplant: More than Immunological Problems
Gelpi, R., Casas, Á., Taco, O., Sánchez-Baya, M., Nassiri, M., Bolufer, M., Paúl, J., Molina, M., Cañas, L., Vila, A., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14062101 · Cited by 5
“After organ transplantation, screening for hyperglycemia should be performed [19].”
İşleyen, E. K., & Özdemir, İ. (2024) · International Journal of Nursing Practice · doi:10.1111/ijn.13316 · Cited by 8
Stice, E. M., Rohde, P., Desjardins, C. D., Gee, K., Shaw, H. E., & Kim, S. H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16170 · Cited by 3
Jia, S., Liang, Q., Zhang, Y., Diao, J., Liu, Y., Ye, Y., Xu, S., Yang, W., Zhao, Y., Ma, B., et al. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00701 · Cited by 4
Regulation of the immune microenvironment by SUMO in diabetes mellitus
Zhuo, Y., Fu, S., & Qiu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1506500 · Cited by 7
“Diabetes is generally divided into four clinical categories, namely type 1 diabetes(T1DM), type 2 diabetes (T2DM), gestational diabetes (GDM) and other speci fi c types of diabetes, and the vast majority of them are type II diabetes, accounting for 90%-95% of all diabetes (3, 78).”
Munns, S., Brown, A. D. H., & Buckberry, S. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1502640 · Cited by 6
Paediatric screening in Italy as a gateway to secondary prevention in type 1 diabetes
Messina, M. F., Pozzilli, P., & Zampetti, S. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112233 · Cited by 5
Rizzi, A., Petrucci, G., Sacco, M., Viti, L., Brioschi, M., Banfi, C., Zaccardi, F., Lancellotti, S., Simone, G., CRISTOFARO, R. D., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112244 · Cited by 5
Bhaduri, G., Sridharan, K., Jain, T., et al. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.102593 · Cited by 3
Wang, N., Li, X., He, R., Zheng, X., Li, M., Nian, S., & Wang, K. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1566345 · Cited by 3
Monteiro, M., Baptista, C. S., Cardoso-Coutinho, D., Landolt, C., Dias‐Pereira, P., & Duarte‐Araújo, M. (2025) · Veterinary Sciences · doi:10.3390/vetsci12060529 · Cited by 6
Zhang, C., Chen, L., & Liu, R. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01967-4 · Cited by 4
“Traditionally, the primary risk factors for T2DM have included obesity, age, and family history [1, 2].”
Yijun, L., Wu, W., Liang, X., Zhou, L., Li, G., Kang, C., Li, W., Huang, C., & Tian, F. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1584626 · Cited by 3
Fan, L., & Zhao, X. (2025) · Hereditas · doi:10.1186/s41065-025-00465-w · Cited by 5
Díaz‐Rizzolo, D. A., Yao, H., Santos‐Báez, L. S., Popp, C. J., Borhan, R., Sordi‐Guth, A., DeBonis, D., Manoogian, E. N. C., Panda, S., Cheng, B., et al. (2025) · Nutrients · doi:10.3390/nu17122026 · Cited by 7
“Fasting glucose (FG) levels are significant predictors of disease progression in prediabetes and type 2 diabetes, and one of the targets of diabetes management [1].”
Liu, D., Li, Q., Jia, R., He, W., Zhao, X., Pan, M., Chen, X., Wang, Y., Zhu, Y., Hou, H., et al. (2025) · BMC Nutrition · doi:10.1186/s40795-025-01119-w · Cited by 6
Ezveci, H., Doğru, Ş., & Yaman, F. K. (2025) · Congenital Anomalies · doi:10.1111/cga.70018 · Cited by 3
“Study Groups (IADPSG), the American Diabetes Association (ADA), 1 and the American College of Obstetricians and Gynecologists (ACOG) 19 were obtained or above these values (the threshold values were as follows: fasting blood glucose 92 mg/dL, 1st hour postprandial value 180 mg/dL, 2nd hour…”
A J-shaped relationship between hemoglobin levels and chronic kidney disease
Yin, R., Li, M., Liu, C., Pu, X., Wen, Y., & Wu, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-08998-w · Cited by 3
“…≥ 90 mmHg was the definition of hypertension 13 , FBP ≥ 7 mmol/L or/and 2 h postprandial plasma glucose ≥ 11.1 mmol/l was the definition of diabetes 14 , SUA level > 420 µmol/l in men or > 360 µmol/l in women was the definition of hyperuricemia 15 , and BMI ≥ 30 kg/m2 was the definition of obesity…”
InfluentialLiu, J., Ssewamala, F. M., An, R., & Ji, M. (2025) · JMIR AI · doi:10.2196/68260 · Cited by 5
“The clinical guidelines generally recommend confirming an elevated test with a secondary measurement for the diagnosis of diabetes [38,43].”
InfluentialQuansah, D. Y., Visintini, S. M., Kim, H., Ahmed, F., Harris, L. A., Dai, N., O’Neill, C. D., Savard, K., Mir, H. R., Coutinho, T. A., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf435 · Cited by 5
Epidemiology and temporal trends of childhood type 1 diabetes in China: an analysis of the GBD 2021
Jin, F., Xie, L., Wang, G., Pan, Y., Wang, C., & Li, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1638187 · Cited by 3
Observational and Genetic Evidence Reveals the Effect of Serum Lipid Levels on COPD Risk
Jia, G., Guo, T., Liu, L., & He, C. (2025) · International Journal of COPD · doi:10.2147/copd.s503030 · Cited by 4
Cavalli, E., Nicoletti, G. R. P., & Nicoletti, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165621 · Cited by 4
“The diagnosis is typically based on persistent hyperglycemia accompanied by autoantibodies against islet antigens such as GAD65, IA-2, insulin, and ZnT8 [5].”
Central hypothyroidism and cardiovascular disease: a Spanish cohort observational study
Guerrero‐Pérez, F., Iglesias, P., Fano, M. P., Rodríguez, M. D. M., Biagetti, B., Cordido, F., Novoa-Testa, I., García-Centeno, R., Fernández, L. G., Araujo-Castro, M., et al. (2025) · HORMONES · doi:10.1007/s42000-025-00707-6 · Cited by 4
Freire, I. V., Ribeiro, Í. J. S., Casotti, C. A., Andrade, D. M. B., Bezerra, D. D., Teixeira, J. R. B., Barbosa, A. A. L., Campos, L. C. G., & Pereira, R. (2025) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-025-00725-w · Cited by 5
“…variables (i.e., gender, race, marital status, BMI, waist circumference [25], smoking habits [current and ex-smokers], level of physical activity [26], estimated sodium intake [27], antihypertensive medication, biochemical data [fasting glucose [28], creatinine [29], HDL-C, LDL-C [30], genotypes).”
Kharsa, C., Sella, G., Kritya, M., et al. (2025) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2025.08.014 · Cited by 3
Alenzi, E. O., AlZabin, A. K., Almajed, E. H., & Alqntash, N. (2025) · Medicina · doi:10.3390/medicina61091583 · Cited by 3
“Prolonged hyperglycemia can lead to damage in various organs, including the eyes, kidneys, nerves, heart, and blood vessels [1].”
He, Y., Zhou, J., Wang, J., Huang, S., Li, H., Cao, J., & Ye, J. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.12.17 · Cited by 5
Li, N., Liu, J., Wu, G., Zhang, J., Liu, L., Zheng, M., Li, H., Li, C., Wen, Y., Ji, J., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112474 · Cited by 5
Hedlund, E., Maziarz, M., Lindahl, T. L., Elding-Larsen, H., Forsander, G., Persson, M., Pundziūtė-Lyckå, A., Åkesson, K., Ludvigsson, J., & Carlsson, A. (2025) · Diabetes Care · doi:10.2337/dc25-0840 · Cited by 3
Alshamsi, F. E., Pathan, A., Yasin, J., Sharma, C., Alshemsi, H. A., Alblooshi, A., AlAwadhi, M. A., Alali, A. A., Alkuwaiti, M., Afandi, B. O., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1687920 · Cited by 3
Sigit, F. S., Cho, S., Kurniawan, F., Jeon, H.-R., Sartika, R. A. D., Tahapary, D. L., & Kwon, H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01957-5 · Cited by 5
“First, DM was diagnosed according to the American Diabetes Association criteria [38] or a self-reported survey question, if participants met any of the following conditions: [1] fasting plasma glucose ≥ 126 mg/dL [2], 2-hour oral glucose tolerance test ≥ 200 mg/ dL [3], random blood glucose ≥ 200…”
Bioinformatics analyses of comorbid mechanisms between psoriasis and type 2 diabetes mellitus
Wang, Z., Mu, J., Zhang, Y., Huang, H., Qin, C., Hu, G., Wang, J., Zhang, P., Cui, H., Huang, W., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-20762-8 · Cited by 3
Mapping Tooth Loss at the Tooth Level: Associations with Demographic, Health, and Behavioral Factors
McCormick, K. M., Mejia, G., Luzzi, L., & Jamieson, L. (2025) · JDR Clinical & Translational Research · doi:10.1177/23800844251384952 · Cited by 4
Chen, J., Fang, Y., Liu, Y., Chen, M., & Tsai, M. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.70187 · Cited by 6
Ao, N., Li, J., Wang, Q., Du, J., Jin, S., & Yang, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-22556-4 · Cited by 5
Optimizing Type 1 Diabetes Screening in People With Family History: A German Perspective
Danne, T., Kapellen, T. M., Widholz, S. A., Wabitsch, M., & Ziegler, R. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251383911 · Cited by 5
“73 From Concept to Practice: Aspects of the Health Care Delivery Task”
Patel, S., Ma, C. S., Fourlanos, S., & Greenfield, J. R. (2025) · Diabetologia · doi:10.1007/s00125-025-06580-7 · Cited by 3
“In prior days, an adult presenting with adult-onset diabetes was more likely to be labelled in a dichotomous manner as either type 2 diabetes or adult-onset type 1 diabetes, yet now there is greater recognition of LADA and secondary or ‘type 3’ forms of diabetes including hybrid forms [12, 31].”
InfluentialKishimoto, M., Tamaru, S., & Odawara, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-23404-1 · Cited by 7
She, C., Tao, Y. K., & Yang, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1687507 · Cited by 3
“Diabetes diagnosis followed the same American Diabetes Association criteria as the NHANES cohort (12).”
Riekki, H., Aitokari, L., Saari, A., Kivelä, L., Huhtala, H., Viitasalo, A., Soininen, S., Haapala, E. A., Lakka, T. A., & Kurppa, K. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01950-y · Cited by 3
“T2D was de fi ned as fasting glucose ≥ 7.0 mmol/L or 2-h glucose >11.0 mmol/L as recommended by the American Diabetes Association [3].”
InfluentialKim, Y., Lee, I., Lee, J., Lee, G., Paek, J. H., Han, S., Kho, Y., Lim, C. S., Choi, K., & Lee, J. P. (2025) · Environment International · doi:10.1016/j.envint.2025.109930 · Cited by 6
Fu, H., Wei, X., & Wirtz, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1718199 · Cited by 3
Adavikolanu, K. R., Ramalingam, C., Balan, K. S., Raghava, K. S. A., Manish, K., Divya, K. N., Ambedkar, Y. R., Babu, V. S., & Kumar, K. A. (2025) · Oncoscience · doi:10.18632/oncoscience.637 · Cited by 3
“…based on the diagnostic criteria set by the American Diabetes Association (ADA), namely: (a) an HbA1c level of ≥6.5 %, (b) a fasting plasma glucose level of ≥126 mg/dl after at least 8 hours of fasting, or (c) a 2-hour plasma glucose level of ≥200 mg/dl during an oral glucose tolerance test [11].”
InfluentialBelfort‐DeAguiar, R., Yeckel, C. W., Elshafie, A., Comarella, A. P., & Hwang, J. J. (2025) · Diabetes Care · doi:10.2337/dc25-1395 · Cited by 5
Elkind-Hirsch, K. E., ARMATTA, M. L., Hames, K. C., & VEILLON, E. W., Jr. (2025) · Expert Review of Medical Devices · doi:10.1080/17434440.2025.2607631 · Cited by 3
Lee, J. H., Heo, S. B., Ryu, H. E., Park, B., & Kwon, Y. (2025) · Yonsei Medical Journal · doi:10.3349/ymj.2025.0046 · Cited by 4
“19 Whether participants were taking cholesterol-lowering medication was determined based on their responses to the questionnaire at the baseline visit.”
Wang, R., Zhang, Y., Li, H., Liu, W., Xu, L., & Lu, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1692746 · Cited by 4
Zhang, Z., Xu, Y., Xu, C., Gao, Q., Wu, X., & Wu, T. (2026) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00054-y · Cited by 3
Metabolic implications of COVID-19 with a focus on lipid profiles and inflammatory markers
Mohamed, F., Gunter, S., Currin, S., Raal, F. J., Kalla, I., & Millen, A. M. E. (2026) · Scientific Reports · doi:10.1038/s41598-026-37439-5 · Cited by 3
“BMI categories were defined as: underweight ( 18.5 kg/m 2 ), normal weight (18.5–24.9 kg/m 2 ), overweight (25–29.9 kg/m 2 ), and obese (≥ 30 kg/m²) 13 .”
InfluentialPeng, R., Ao, Y., Cen, E., Chen, J., Huang, Z., Xiaoying, F., Kuang, J., Lai, S., & Zhang, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1711660 · Cited by 3
“The participants were diagnosed with T2DM according to the 1999 World Health Organization diagnosis criteria and the 2025 classi fi cation of diabetes mellitus (21, 22).”
Chen, Y., Zeng, H., Luo, Z., Hu, H., & Wang, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1701371 · Cited by 4
Breathomics-Guided Solid-State Sensor for Noninvasive Point-of-Care Diabetes Screening
Fan, T., Zhang, Y., Liu, F., Liu, Y., Sun, S., Ding, X., Zhang, C. H., Jia, X., Wang, B., Sun, P., et al. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c07225 · Cited by 3
Piroș, T., Lupușoru, R., Moleriu, L. C., Muntean, C., Moleriu, R. D., Cîmpian, D. M., Cincu, M.-G., Strete, E. G., Timofte, A. G., & Marin, R.-C. (2026) · Nutrients · doi:10.3390/nu18060977 · Cited by 4
Gugliandolo, S., Morciano, C., Leccisotti, L., Capece, U., Giuseppe, G. D., Mezza, T., Ciccarelli, G., Soldovieri, L., Brunetti, M., AVOLIO, A., et al. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70162 · Cited by 5
Topical corticosteroid use and risk of type 2 diabetes mellitus: a nationwide cohort study
Kim, H., Lee, J. H., Bae, Y., Kim, H., & Song, S.-W. (2026) · British Journal of Dermatology · doi:10.1093/bjd/ljag165 · Cited by 3
Choi, J. W., Kim, T. H., Park, J.-S., & Lee, C. H. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010089 · Cited by 3
Yagi, K., Inagaki, M., Asada, Y., Komatsu, M., Ogawa, F., Horiguchi, T., Yamaaki, N., Shikida, M., Origasa, H., & Nishio, S. (2024) · Medicina · doi:10.3390/medicina60020329 · Cited by 3
Diabetic patients and postoperative complications in colorectal surgery
Păunică, I., Silaghi, A. M., Bălan, D. G., Socea, B., Bălălău, C., Groseanu, F. S., Popescu, G. A., Epistatu, D., & Constantin, V. D. (2024) · Journal of Mind and Medical Sciences · doi:10.22543/2392-7674.1495 · Cited by 6
“Values above 200 mg/dL for glucose and more than 6.5% for glycated hemoglobin are diagnostic for one of the two forms of diabetes [7].”
Influential
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Selvin, E., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Gaglia, Jason L.
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Selvin, Elizabeth
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S20-S42
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725812
- OpenAlex
- W4389560718
- Cited by
- 2,086
- References
- 232
- Citations by year
- 2026: 771 · 2025: 903 · 2024: 408 · 2023: 1
- FWCI
- 74.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes diagnosis, diabetes classification, diabetes mellitus, clinical guidelines, American Diabetes Association standards of care, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.